Fate Therapeutics
FATE
NZ$1.91
Share price
-0.87%
Change (1 day)
-70.10%
Change (1 year)
Categories
Fate Therapeutics (FATE) - Total debt
Total debt on the balance sheet as of March 2025 : NZ$0.13 Billion
According to Fate Therapeutics 's latest financial reports the company's total debt is NZ$0.13 Billion. A company’s total debt is the sum of all current and non-current debts.
Fate Therapeutics - Total debt on balance sheet (from 2012 to 2025)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2024-12-31 | NZ$0.15 B | -7.65% |
| 2023-12-31 | NZ$0.16 B | -4.93% |
| 2022-12-31 | NZ$0.17 B | 2.45% |
| 2021-12-31 | NZ$0.16 B | 24.66% |
| 2020-12-31 | NZ$0.13 B | 237.27% |
| 2019-12-31 | NZ$39.98 M | 80.19% |
| 2018-12-31 | NZ$22.18 M | 6.42% |
| 2017-12-31 | NZ$20.85 M | 35.13% |
| 2016-12-31 | NZ$15.42 M | -42.1% |
| 2015-12-31 | NZ$26.64 M | 6.48% |
| 2014-12-31 | NZ$25.02 M | 1087.36% |
| 2013-12-31 | NZ$2.1 M | -52.79% |
| 2012-12-31 | NZ$4.46 M | -27.99% |
| 2011-12-31 | NZ$6.2 M |
Total debt for similar companies or competitors
| Company | Total debt/th> | differencediff. | Country |
|---|---|---|---|
 Sarepta Therapeutics
SRPT | NZ$2.24 B | 1,512.58% | 🇺🇸 USA |
 Becton Dickinson BDX | NZ$32.25 B | 23,025.20% | 🇺🇸 USA |
 PTC Therapeutics
PTCT | NZ$0.65 B | 367.56% | 🇺🇸 USA |
 Avidity Biosciences RNA | NZ$9.99 M | -92.83% | 🇺🇸 USA |
 Neurocrine Biosciences
NBIX | NZ$0.74 B | 437.03% | 🇺🇸 USA |